CytomX Therapeutics, Inc. (CTMX) compared with its closest peers (NGNE, GYRE, NVCT, BBOT, MNPR). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Neurogene Inc. (NGNE) | $772.74M | -4.9 |
| Gyre Therapeutics, Inc. (GYRE) | $768.30M | 352.0 |
| Nuvectis Pharma, Inc. (NVCT) | $765.34M | -5.7 |
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $727.98M | -2.9 |
| Monopar Therapeutics Inc. (MNPR) | $725.08M | -35.4 |
| Phathom Pharmaceuticals, Inc. (PHAT) | $718.00M | -5.5 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Zevra Therapeutics, Inc. (ZVRA) | $701.40M | 6.4 |
| Assembly Biosciences, Inc. (ASMB) | $700.00M | -62.0 |
| Sensei Biotherapeutics, Inc. (SNSE) | $670.82M | -0.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
CTMX overview · CTMX earnings · CTMX financials · CTMX KPIs · CTMX documents · CTMX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.